Personalized neoantigen T cell therapy for glioblastoma
Neoantigen-specific Adoptive T Cell Therapy for Glioblastoma, IND-BB-13135, protocol submitted 04/25/2020
['FUNDING_R01'] · TVAX BIOMEDICAL, INC. · NIH-10710039
This approach uses a vaccine made from your tumor plus your own activated T cells to help people with newly diagnosed, surgically removable glioblastoma fight their cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TVAX BIOMEDICAL, INC. (nih funded) |
| Locations | 1 site (OLATHE, UNITED STATES) |
| Trial ID | NIH-10710039 on ClinicalTrials.gov |
What this research studies
If I join, doctors would use pieces of my removed tumor to make a neoantigen vaccine and boost immune response with an adjuvant. They would collect my blood to harvest tumor‑specific T cell precursors, grow and activate those T cells outside the body, and then give the cells back along with short courses of interleukin‑2. The treatment is autologous, meaning it uses my own cells, and has been reported to cause only short, mild to moderate side effects. The goal is to increase tumor‑specific T cells that can seek out and kill residual cancer cells after surgery.
Who could benefit from this research
Good fit: Ideal candidates are people with newly diagnosed, surgically resectable glioblastoma who can provide tumor tissue and undergo blood collection for T cell manufacturing.
Not a fit: Patients with tumors that cannot be removed, those unable to tolerate surgery or leukapheresis, or with medical conditions that preclude immunotherapy may not be able to participate or benefit.
Why it matters
Potential benefit: If successful, this could help reduce tumor recurrence and extend survival by strengthening a personalized immune attack on glioblastoma with generally low short‑term toxicity.
How similar studies have performed: Related neoantigen vaccines and adoptive T cell therapies have shown promising results in some cancers, but this combined, personalized approach remains relatively novel for glioblastoma.
Where this research is happening
OLATHE, UNITED STATES
- TVAX BIOMEDICAL, INC. — OLATHE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WOOD, GARY W. — TVAX BIOMEDICAL, INC.
- Study coordinator: WOOD, GARY W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.